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Development and Implementation of a Standardized Protocol for Nurse
Practitioners Working in an AUD Treatment Telehealth Program
Abstract
Background
Alcohol Use Disorder (AUD) is a public health concern in the United States with the National
Institutes of Health citing alcohol as the third leading preventable cause of death in the United
States. Ria Health is a growing telehealth provider delivering AUD treatment through
pharmacotherapy combined with behavioral health counseling. Ria Health was founded in 2017
by board-certified addiction specialist, Dr. John Mendelson.
Local Problem
Ria Health employs six California licensed nurse practitioners. Among the six are two nurse
practitioners who have not yet met all the California provisions to practice independently without
protocols. Ria Health has not put any standardized protocols in place. A standardized protocol at
Ria Health is required by state law for these two nurses who are practicing as an advanced
practice nurse.
Methods
This DNP project involved the creation of an evidence-based standardized protocol for alcohol
use disorder. The Student Satisfaction and Self-Confidence in Learning questionnaire was
disseminated via email to the participants after the orientation to the standardized protocol. This
is a 13-item instrument designed was designed by National League for Nursing to measure
student satisfaction (five items) with an activity and self-confidence in learning (eight items)
using a five-point Likert scale. The outcome measure was analyzed using Microsoft Excel.
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Intervention
The creation and implementation of a standardized protocol for nurse practitioners employed at
Ria Health is a significant quality improvement project. Not only are standardized protocols
required by California law for some nurse practitioners, these protocols would also contribute to
the maintenance of high standards of care for patients through evidence-based practices. Because
the nursing curriculum for most nurse practitioners does not include addiction medicine, nurse
practitioners may not have confidence with medication-assisted treatment (MAT) for AUD. The
standardized protocols can increase the nurse practitioner’s confidence, improve patient care
outcomes, and ensure compliance with state law. The project goal was to implement a
standardized protocol at Ria Health by May 2022.
Results
The standardized protocol for alcohol use disorder was successfully implemented for only one
out of two nurse practitioners. The first nurse was satisfied with the orientation to the
standardized protocol as it had increased her self-confidence in learning. Moreover, this nurse
was an active contributor as an editor to the protocol. The second nurse was dissatisfied with the
orientation and did not find the protocol helpful. This second nurse did not want to participate in
the implementation of the protocol.
Conclusion
Standardized protocols are required to be developed with the nurse practitioner delivering the
care and not just by administrators or physicians, who do not understand the practice of the nurse
practitioner as well as the nurse practitioner providing the service. These protocols are the legal
authority for the nurse practitioner to exceed the usual scope of practice from a registered nurse.
Without standardized protocols, the nurse practitioner is legally vulnerable, and may be subject
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to discipline from the state board of nursing for practicing medicine which is beyond their scope
of nursing practice. This DNP project may also benefit other AUD programs which may not have
standardized protocols in place.
Keywords: nurse practitioner, NP, advance practice nurse, APRN, alcohol use disorder, AUD,
standardized procedure, standardized protocols, guideline, protocol, procedure.
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Development and Implementation of a Standardized Protocol for Nurse
Practitioners Working in an AUD Treatment Telehealth Program
Introduction
Background
Alcohol Use Disorder (AUD) is a public health concern in the United States. The
mortality of alcohol abuse and addiction in the US is as follows: more than 95,000 deaths per
year which approximates to 261 deaths per day; 29 years of life lost per person; and liver disease
accounts for one-third of all alcohol-associated mortality (CDC, 2021). The National Institutes of
Health cites alcohol as the third leading preventable cause of death in the United States (NIH,
2018). Moreover, the economic burden of alcohol misuse cost the United States $249.0 billion in
2010 (CDC, 2019). The COVID-19 pandemic has changed many people’s drinking habits. The
Nielsen survey reported a 54% increase of alcohol sales nationwide during the first week of the
shelter-in-place mandates in March 2020 (Pollard, Tucker, & Green, 2020). Pandemic-related
stress (45.7%), increased alcohol access (34.4%), and boredom (30.1%) were the top main
reasons for increased alcohol consumption (Grossman, Benjamin-Neelon, & Sonnenschein,
2020). Treatment for AUD is complex and challenging. Nurse practitioners can fulfill an
important role in the healthcare system by serving as frontline clinicians to assess and to
implement treatment plans for AUD (Cadet & Tucker, 2019).
Problem Description
Ria Health, a telehealth provider, is currently licensed to treat AUD clients in fifteen
states and has goals in expanding services to all fifty states in the near future. Ria Health began
employing nurse practitioners due to growth in the demand for services and has plans to employ
more nurse practitioners. Currently, Ria Health has not put any standardized protocols in place.
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In California, standardized protocols are the legal mechanism for nurse practitioners to perform
advance practice functions outside the scope of a registered nurse which would otherwise be
considered the practice of medicine (BRN, 1998). Beginning January 1, 2021, AB 890 will allow
some nurse practitioners to practice independently in particular healthcare settings where at least
one physician practices with the nurse practitioner. Those nurse practitioners who meet certain
educational and practice requirements are allowed, under this new law, to perform medical
functions without standardized protocols (A.B. 890, 2020). Because not all nurse practitioners
may have the education and practice requirements specified in A.B. 890 and the full measure of
A.B. 890 is not in effect until 2023, the creation and implementation of standardized protocols
for AUD at Ria Health is still required by California state law for many nurse practitioners. Not
only is using standardized protocols a legal requirement for many nurse practitioners, but it also
contributes to the maintenance of high standards of care for patients through evidence-based
practices (Chidgey, Leng, & Lacey, 2007). The implementation of standardized protocols at Ria
Health will be a quality improvement from current practices. Most nurse practitioners did not
have addiction medicine in their nursing curriculum and therefore may not have confidence with
medication-assisted treatment (MAT) for AUD. The standardized protocols can increase the
nurse practitioner’s autonomy and body of knowledge, in addition to providing guidance for
AUD treatment and improving patient care outcomes. This project may also benefit other
addiction programs aiming to develop, to revise or to improve their practices.
Setting
Ria Health is a growing telehealth provider delivering evidence-based alcohol addiction
treatment through a mobile care delivery platform. The clinic office is located in San Francisco,
CA. This program is intended for clients who are looking to control their alcohol intake or to

DEVELOPMENT AND IMPLEMENTATION OF A STANDARDIZED PROTOCOL

10

become abstinent. Ria Health uses pharmacotherapy or medication-assisted treatment (MAT)
combined with behavioral health counseling to help clients overcome their AUD. The company
was founded in 2017 by Dr. John Mendelson, a board-certified addiction specialist who had been
Ria Health’s sole physician until 2020 when psychiatrist Dr. Paul Linde was hired. All employees
work remotely from their home. Patients do not physically go to Ria Health. All patient care is
done remotely, by use of telephone or teleconference.
Specific Aim (Purpose)
The aim of this DNP student quality improvement project was to implement a
standardized protocol for California licensed nurse practitioners at Ria Health by May 2022.
Available Knowledge
PICO(T) Question
Standardized protocols for nurse practitioners ensure adherence to a standard of care and
provide effective care aimed at positive patient outcomes (Singleton & Levin, 2008). The
assessment, diagnosis, treatment, and management of specific conditions may be included in
such standardized protocols. Nurse practitioners have the discretion either to develop their own
standardized protocols in collaboration with the supervising physician, or to adopt protocols
developed by specialty organizations or groups (Singleton & Levin, 2008). Accordingly, this
raises the PICOT question: Will the implementation of standardized protocols result in higher
confidence levels of knowledge among nurse practitioners employed at Ria Health after its
implementation? In order to answer this question, standardized protocols along with associated
processes were developed based on scientific evidence.
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Search Methodology
A literature review was conducted with search terms inclusive of three keywords, with
each word having an alternative name. The three keyword permutations are: (A) nurse
practitioner/NP/advance practice nurse/APRN, (B) alcohol use disorder/AUD, and (C)
standardized procedure/standardized protocols, or guideline/protocol/procedure. The search was
performed using Medline, CINAHL, Academic Search Premier, Cochrane reviews, and Google
Scholar. No literature was found in any of the search engines that included all three keywords
within A, B and C, or two keywords within A and B.
The combination of A and C yielded 13 articles. One out of these 13 articles remained
after excluding those older than ten years and excluding guidelines that pertained to protocols on
medical or social screenings. Google scholar found one dissertation about the development of an
SP for Nurse practitioners in a long-term care setting. This dissertation was not published in a
peer-reviewed journal; however, due to the limited literature available, dissertations were
included in the literature analysis as a framework for this DNP project. The keywords of B and C
yielded two results, with one being another dissertation. Articles on study protocols were
excluded.
To broaden the search, keyword (B) was replaced with the following: (D) substance use
disorder, (E) addiction, and (F) alcohol. The combination of A and C with either D, E or F did
not yield any articles. Pairing just A with either D, E or F yielded one article that met criteria,
but this article addresses literature about disciplinary procedures for nurses who have addictions
or alcoholism, and, therefore, was excluded. Pairing just C with either D, E or F was slightly
more productive. The combination of C and D yielded one relevant article. The combination of
C and E yielded six articles, but all of them concerned smoking or opioid use disorder, and,
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therefore, were excluded. The combination of C and F yielded in 19 articles. Only one was
relevant, but this was a repeated article found earlier with combination of B and C. In summary,
eight articles were deemed pertinent.
The literature review also included a search on clinical guidelines in relation to
developmental tools. Search term used was “clinical guideline” in the title and published within
the last 12 years in the English language. The search yielded 208 results. After the articles that
were specific to a condition or disease were excluded, only a few articles remained that pertained
to general clinical guidelines. The John Hopkins Evidence-Based Practice Research Appraisal
Tool (2017) was used to evaluate the level and quality of evidence of these articles. (See
Appendix B for the Evaluation Table).
Integrated Review of the Literature
The articles pertaining to general clinical guidelines provide the framework for drafting
new standardized protocols. The article by Chidgey, Leng, and Lacey (2007) identifies the
National Institute for Health and Care Excellence (NICE) as a key organization that publishes
clinical guidelines to improve healthcare through evidence-based practices. The article discusses
the “robust methodology used to develop NICE guidance and NICE’s approach to economic
analysis, the mechanisms by which clinicians are involved in guidance development, the
practical support available to aid implementation of guidance, and the advantages to doctors (and
other clinicians) of using NICE guidance” (p. 448). NICE uses an independent committee in its
development process with the overall goal to provide guidance at the national level. Although the
aim of this DNP project is specifically for one clinic setting, incorporating the pertinent elements
from NICE’s guideline development is essential to make protocols evidence based.
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GRADE (Grading of Recommendations Assessment, Development and Evaluation) is a
method of rating the quality of evidence in a guideline and the strength of outcomes from its
recommendations (Schünemann, Best, Vist, and Oxman (2003). NICE began integrating
GRADE across its clinical guideline program in 2007 to enable separation of rulings about the
evidence quality from rulings about the strength of the recommendation (Thornton et al., 2013).
Although GRADE has been positively received by guideline developers, the “application of
imprecision and presenting results from analyses considering more than two alternative
interventions” requires refinement (Thornton et al., 2013, p. 131).
Standardized protocols for nurse practitioners ensure adherence to a standard of care and
provide effective care aimed at positive patient outcomes (Singleton & Levin, 2008). The
assessment, diagnosis, treatment, and management of specific conditions may be included in
such protocols. Nurse practitioners have the discretion to either develop their own protocols in
collaboration with the physician, or adopt protocols developed by specialty organizations or
groups (Singleton & Levin, 2008). These two authors are nursing faculty at Pace University and
their article describes a teaching-learning strategy to appraising clinical protocols critically to
determine whether those protocols qualify as evidence-based practice.
The application of the general framework for the development of standardized protocols
on AUD specifically for nurse practitioners is difficult because no literature specifically
addresses standardized protocols on AUD specifically for nurse practitioners. Only a couple of
standardized protocols for nurse practitioners were found in peer-reviewed journals within the
last ten years. Powel and Engberg (2018) implemented the use of a glycemic management
protocol at a primary care clinic as a tool to provide guidance and a framework for decision
making for the nurse practitioner in escalation of drug management for patients with type-2
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diabetes. The protocol was not created by the authors, but was based on the REMEDIES 4D
protocol. This article demonstrated that protocols assist Nurse practitioners in remaining
autonomous and can provide “positive patient outcomes” without the need for constant physician
authorization for medication adjustment (Powel & Engberg, 2018). For Marshall’s (2016)
dissertation, she developed an evidence-based practice guideline for nurse practitioners with
DNP degrees employed in long-term care settings. After the creation of the guideline, Marshall
used the Appraisal of Guidelines for Research and Evaluation (AGREE) Instrument to address
the variability in the quality of her developed guideline. The substance of Marshall’s dissertation
is unrelated to AUD, but her framework on development of guidelines is central to this paper.
She also encountered a gap in literature on her topic and explained the likely cause for this gap to
be “the fact that DNP is still a relatively new degree” (Marshall, 2016, p. 16). Similarity, in
relation to the topic of this paper, the NP role in treatment for AUD is apparently quite new.
Steven Ling presented a paper titled “Nurse Practitioners in Drug and Alcohol: Where
Are They?” at the 2007 annual Australian nursing conference. Ling introduced the idea of having
Nurse practitioners employed in the drug and alcohol setting to his Australian audience as a way
to address the shortage of appropriate trained medical staff in the workforce. His article,
proposing the expansion of the role of nurse practitioners throughout Australia, was in harmony
with the Australian government announcing $59.7 million funding for nurse practitioner
education during that time period. However, Ling mentions that the full potential of nurse
practitioners in the substance use realm would not be realized until Australian nurse practitioners
have access to healthcare financial arrangements for mid-level providers.
Since Ling’s 2007 article, the nurse practitioner educational programs in the United
Stated have slowly begun integrating substance use into their curriculum. Covington et al.,
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(2018) published a study about incorporating, into the curriculum for nurse practitioner students,
information on substance use screening and brief interventions in the clinical setting. The
students were taught using a process called SBIRT (screening, brief interventions, and referral to
treatment) which was developed by the Substance Abuse and Mental Health Services
Administration (SAMHSA). The AUDIT and DAST tools were used for alcohol and drug use,
respectively. This study used univariate descriptive statistics and a one-way ANOVA to
demonstrate the positive effects of increasing students’ knowledge and confidence in screening
for substance use, which, in turn, may result in better patient responses to interventions using
motivational interviewing to reduce substance use or to refer to addiction specialists for
treatment. Hence, this is “the first step toward highlighting the important role APRNs can play in
addressing at-risk patients in clinical settings” (Covington et al., 2018, p. 127).
Summary/Synthesis of the Evidence
With the recent proposal from Covington et al., the absence of literature on nurse
practitioners in the treatment of AUD is not surprising. In order to create an AUD standardized
protocol for nurse practitioners, the following three literature analyses were used as an outline
for its development. First, Rundio (2013) developed and successfully implemented an alcohol
withdrawal protocol in a residential addiction treatment facility. Prior to implementation, the
clinicians were writing the withdrawal orders daily. The author noticed the medication orders
were similar daily. Therefore, having a protocol that addressed all orders for the entire duration
of the patient’s admittance at the facility could facilitate the patient’s treatment process by
decreasing the variance of patient care and the number of written orders. Rundio collaborated
with the facility’s Director of Nursing and Medical Director on protocol creation and extracted
relevant evidence-based research for the best treatment modalities. The protocol was

DEVELOPMENT AND IMPLEMENTATION OF A STANDARDIZED PROTOCOL

16

implemented once the Medical Director approved it. The protocol’s effectiveness was then
evaluated by monitoring patient outcomes preceding the 3 months after protocol implementation.
Rundio’s protocol was so efficacious that two additional protocols were created for
implementation as a result of the initial protocols’ usefulness. The article did not discuss any
research limitations.
Second, Gonzalez-Mendez (2017) created an evidence-based guideline with an algorithm
to aid medical screeners at a correctional facility to screen appropriately for AUD in incoming
inmates in order to prevent dangerous incidents of alcohol withdrawal syndrome. The adoption
of the AGREE II instrument assisted the author in guideline development. The Delphi technique
was used for settlement of the proper guideline; this included nine correctional health experts
(nurses and physicians) from nine regions across the United States. The ACE Star Model was
suggested as the framework for systemically implementing the evidence-based guideline. The
limitation of this study was the inability for implementation due to the federal government’s
rigorous and time-exhausting practices for review, approval, and change.
Third, the American Psychiatric Association (APA) practice guideline for
pharmacological treatment of patients with AUD (2018) is thorough in discussing the FDAapproved drugs used in AUD and their benefits versus harm. The first-line agents for AUD are
naltrexone and acamprosate. The APA also discussed topiramate and gabapentin, which are not
FDA approved for AUD but have shown efficiency for AUD. This guideline assists clinicians
with appropriate medication selection, especially when the patients with AUD have complex
comorbidities. The guideline is a recommendation; the ultimate decision lies on the treating
clinician with collaboration from the patient to incorporate personal and sociocultural
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preferences in order to create and maintain the therapeutic alliance and adherence to treatment
(APA, 2018).
The information gained from this literature review demonstrated the importance of
having an evidence-base protocol not only for legal purposes, but also for patient safety and
improved quality of services. The challenge was the gap in literature about standardized
protocols for nurse practitioners treating AUD.
Rationale
Lewin’s Change Theory was applied in this quality improvement project as it provided
the fundamental principles for change. This theory is a three-stage model of change known as
unfreeze-change-refreeze model that requires prior learning to be rejected and replaced
(Wojciechowsk, et al., 2016). Ria Health did not have any standardized protocols in place. Nurse
practitioners had no guidance or framework on care delivery., Therefore, the quality of patient
care is variable. Application of the Change Theory would “unfreeze” by having Ria Health exit
the mindset of ad hoc judgments, or freelance mentality. Next, “change” by implementing the
standardized protocol. Last, “refreeze” when the use of standardized protocol becomes the
standard operating procedure (See Appendix C).
Benner’s Novice to Expert Theory was also applied for this DNP project. Benner (1984)
identifies five possible nursing expertise levels: novice, advanced beginner, competent,
proficient, and expert (See Appendix D). The novice stage begins in nursing school. In the next
stage, advanced beginner, these nurses use analytical principles or rules to determine what
actions are required for the immediate situation. This authors’ creation and implementation of the
protocol serves as the foundation for the advanced beginner nurse practitioner employed at Ria
Health. This brings forth the next stage of being competent. Benner (1984) describes this stage
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in which nurses can respond to the clinical situations but lack the ability to recognize situations
as a whole. With increased knowledge and experience, proficient nurses are able to see situations
in a larger context and have more capability to know and respond to varying circumstances. The
last level, expert nurse, is achieved when the nurse “no longer relies on rules to connect his/her
understanding of the situation to an appropriate action” but has the “intuitive grasp” to make
critical clinical decisions efficiently while grasping the entire situation. Accordingly, the expert
nurse is able to diagnose accurately and to respond quickly, without wasteful consideration of
ineffective possibilities.
Methods
Context
The major stakeholders at Ria Health include John Mendelson (Chief Medical Director),
Paul Linde (Medical Director), Tom Nix (CEO), David Deacon (COO), Bob Nix (CTO),
California licensed nurse practitioners, and the Ria Health patients. Dr. Mendelson is aware that
employing nurse practitioners would be cost advantageous to him and it would allow him to have
more time to focus on the corporate aspect of Ria Health. He was not aware that a standardized
protocol is required by California law for nurse practitioners, but he was open to the need for
change. The California licensed nurse practitioners at Ria Health will have a participatory role in
receiving education on the evidenced-based AUD standardized protocol approved by Dr.
Mendelson.
Intervention
The creation and implementation of a standardized protocol for nurse practitioners
employed at Ria Health is a significant quality improvement project. Not only are standardized
protocols required by California law for some nurse practitioners, these protocols would also
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contribute to the maintenance of high standards of care for patients through evidence-based
practices. Because the nursing curriculum for most nurse practitioners does not include addiction
medicine, nurse practitioners may not have confidence with medication-assisted treatment
(MAT) for AUD. The standardized protocols can increase the nurse practitioner’s confidence
while improving patient care outcomes. The project goal was to implement a standardized
protocol at Ria Health by May 2022.
Gap Analysis
Standardized protocols are required to ensure that nurse practitioners function within
their scope of practice to meet the health care needs of their patients in states where nurse
practitioners lack full independent practice authority. Ria Health has not had any standardized
protocols in place since hiring their first nurse practitioner in 2018. Consequently, nurse
practitioners have no guidance or framework on care delivery, and the quality of patient care
varies. Moreover, nurse practitioners are legally vulnerable without any standardized protocols in
place since AB 890 is not effective until 2023. (See Appendix E for the Gap Analysis chart).
Gantt Chart
Prospectus development began over the course of the 2020 fall semester with Ria
Health’s stakeholders officially approving the DNP project on 14 February 2021. (See Appendix
F for the Organizational Support Letter). The project lead developed the proposed AUD SP and it
has been approved in March 2021 by Ria Health’s Medical Director (See Appendix G for the
SP). The implementation of the standardized protocol concluded in early April 2022, with data
synthesis completion done within a week from implementation. (See Appendix H for GANNT
Chart).
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Work Breakdown Structure
The Work Breakdown Structure (WBS) for this project has three key categories:
planning, implementation, and evaluation. Planning was the largest part of the project. The first
step of planning was the need analysis or clinical implications for doing the project. This was
followed by SWOT analysis and the drafting of a GANTT chart to help with the timeline. From
there, the literature review was completed. This led to the final step of development of a basic
framework. When the project was approved by Ria Health’s Medical Director, the AUD
standardized protocol was created and, shortly thereafter, was approved for implementation. The
project was approved for implementation from USF’s Committee Chair and Committee Member
(See Appendix I for the WBS Chart).
Responsibility/Communication Matrix
Ongoing communication with stakeholders was held primarily via email, telephone and
occasionally via Zoom sessions. Ongoing mentorship by the DNP chair was on an as-needed
basis throughout the duration of DNP project via Zoom (See Appendix J for the communication
matrix).
SWOT Analysis
Because Ria Health is small, it has developed a set of traditions that inhibit productive
change. The small size of the organization, however, can theoretically make the implementation
of change easier. The opportunities offered by this project were exciting. The market seems to
have a demand for Ria Health’s service now. Due to restrictions designed to limit transmission
of COVID-19, people are at home and are drinking more (Pollard, Tucker, & Green, 2020). The
biggest strength is having Professor Radasa employed there. One major threat to the project was
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COVID-19, which virtually stalled the implementation of the DNP project. A more detailed
SWOT analysis is included in Appendix K.
Budget
The materials chosen for use in this project were selected based on sustainability as they
were easily accessible, reproducible, and free on the internet. The total expenses for this project
was $15,875. The major expense was for the DNP student/project directors’ fee at $15,750
(payment-in-kind), followed by $100 in office materials, and $25 (payment-in-kind) to train two
California licensed nurse practitioners in a 15-min session. All cost and fees involved in the DNP
project were solely absorbed by the DNP student/project director (See Appendix L for a detailed
budget chart).
Study of the Intervention
The goal of the DNP project was to implement an evidenced-based AUD standardized
protocol for all California-licensed nurse practitioners who have not meet the California state
requirements to practice independently at Ria Health. Among the six California licensed nurse
practitioners at Ria Heath, only four of them are qualified to have full independent practice
authority under AB 890. The requirements and the format of the standardized protocol were
adapted from the California Board of Nursing. Additionally, a flow chart is attached to the
standardized protocol as a visual guide to help ease the use of the standardized protocol (See
Appendix G, Figure 1). The standardized protocol will legally protect the Ria Health nurse
practitioners who are licensed in California and are practicing beyond the scope of practice for
registered nurses. The two California licensed nurse practitioners who were required to work
under standardized protocols were given an orientation to the rules and regulations imposed by
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the California Board of Nursing and to the proposed AUD standardized protocol. These nurse
practitioners were also invited to be a contributing editor for the protocol.
Outcome Measures
CQI Method and Data Collection Tools
The Student Satisfaction and Self-Confidence in Learning instrument was used to
measure the nurse practitioner’s satisfaction and their self-confidence in learning about the AUD
standardized protocol (Appendix M). The tool consists of a 13-item questionnaire using a fivepoint Likert scale survey. The Student Satisfaction and Self-Confidence in Learning tool, is taken
from the National League for Nursing (2004) and has a Cronbach’s alpha reliability in
satisfaction and self-confidence of 0.94 and 0.87, respectively. In order to make the tool relevant
to the Ria Health setting, the word “simulation” within the questionnaire was replaced with
“orientation” and “medical surgical curriculum” was replaced with “alcohol use disorder
curriculum” (See Appendix N). The questionnaire was emailed to all participants after
orientation to the AUD standardized protocol.
Analysis
An analysis using Microsoft Excel was performed to measure the level of the nurse
practitioner’s satisfaction with the training and self-confidence levels in learning after the
orientation training to the AUD standardized protocol. The raw data was extrapolated into a barchart (see Appendix O).
Ethical considerations
This quality improvement project was approved as non-research; therefore, no IRB
approval was needed and there were no privacy concerns. The project falls under ANA’s Ethical
Standards Provision 7.2, “Contributions through developing, maintaining, and implementing
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professional practice standards” and under Jesuit values. St. Ignatius’s original statement of
purpose for the Jesuit Order, included the need “to reconcile the estranged.” This project supports
that objective. The implementation of this quality improvement project enhances the quality of
care for those whose AUD leaves them estranged from family, colleagues and community, thus
aligning with the mission and values of USF.
Results
The Student Satisfaction and Self-Confidence in Learning instrument was emailed to
the two participants immediately after the conclusion of the orientation to the AUD
standardized protocol. In the 13-item questionnaire, the first five questions measure the
participants satisfaction with current learning. The remaining eight questions measures the
participants self-confidence in learning.
The following are the questions:
(1) The teaching methods used in this presentation was helpful and effective.
(2) The presentation provided me with a variety of learning materials and activities to
promote my learning the AUD curriculum.
(3) I enjoyed how my presenter taught the presentation.
(4) The teaching materials used in this presentation was motivating and helped me
(5) The way my presenter taught the presentation was suitable to the way I learn.
(6) I am confident that I am mastering the content of the presentation activity that my
presenter presented to me.
(7) I am confident that this presentation covered critical content necessary for the
mastery of AUD curriculum.
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(8) I am confident that I am developing the skills and obtaining the required
knowledge from this presentation to perform necessary tasks in a clinical setting.
(9) My presenter used helpful resources to teach the presentation.
(10)

It is my responsibility as the student to learn what I need to know from this

presentation activity.
(11)

I know how to get help when I do not understand the concepts covered in the

presentation.
(12)

I know how to use this presentation activity to learn critical aspects of these

skills.
(13)

It is the presenter's responsibility to tell me what I need to learn of the

presentation activity content during class time.

This questionnaire uses a five-point Likert scale survey. The scoring systems is as
follows:
1 = Strongly disagree with the statement
2 = Disagree with the statement
3 = Neither agree or disagree with the statement
4 = Agree with the statement
5 = Strongly agree with the statement
Ultimately, a score of 5 is the highest possible score, which translates to a
positive advancement in learning in terms of satisfaction or confidence. On the other
end of the spectrum, a scoring of 1 indicates the lowest possible score, which means
the standardized protocol made no impact on the participant.

24

DEVELOPMENT AND IMPLEMENTATION OF A STANDARDIZED PROTOCOL
The first participant, NP #1, marked 5 (strongly agree) across almost all
questions except marked 4 (agree) for questions 1, 3, and 13. The second participant,
NP #2, marked 1 (strongly disagree) for all questions in the questionnaire. (See
Appendix O).
Discussion
Summary
The aim to implement an alcohol use disorder standardized protocol at Ria
Health for California licensed nurse practitioners was not 100% achieved. Success was
measured to be at fifty percent. NP #1 was satisfied with the orientation to the
standardized protocol and marked 5’s in their confidence levels, meaning the protocol
was helpful. NP #1 was enthusiastic and actively involved in collaborating with the
DNP student/project director in editing the protocol. NP #1 was aware of the legal
requirement in California for nurse practitioners, and felt it was a relief that the DNP
student/project director was implementing this AUD standardized protocol.
NP #2 indicated that this quality improvement project was not helpful given
their extensive experience in clinical practice. NP #2 was not aware that a standardized
protocol was requirement for those who have not completed the “transition to practice
in California” yet. NP #2’s license had only been endorsed in California for 10 months.
This participant was not happy, stated having had over 6 years of experience working
independently in other states. Consequently, NP #2 did not volunteer to provide
feedback or collaborate with the protocol.
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This DNP project has assisted in bringing a needed standardized protocol for
one Ria Health nurse practitioner. NP #1 is now practicing legally in California as a
nurse practitioner, whereas NP#2 has chosen to practice illegally.
Interpretation
The findings of this DNP quality improvement project proved to be less
successful than anticipated. Ria Health has now published the standardized protocol
within its provider handbook (available via their intranet system); however, this is only
one of two parts of the implementation process. The California Code of Regulations
(CCR section 1474; Medical Board of California, Title 16, CCR Section 1379) requires
the nurse practitioner protocol to be signed and dated by both the medical director and
by those nurse practitioners who have not yet met all the provisions to practice
independently without protocols.
This lack of enforcement from the Ria Health’s leadership team support Lewin’s
Change Theory, which is the framework that guided this DNP project as it. The driving
force from the DNP student/project director is not strong enough to affect the
movement from the existing equilibrium at Ria Health. Unless nurse practitioners are
advocating to have a standardized protocol agreement form signed off by the medical
director and themselves, or if the state nursing board intervenes, Ria Health is not
actively involved in keeping in compliance with California law. Moreover, additional
protocols will need to be created and implemented in the future to incorporate
requirements from all 51 united states jurisdictions as Ria Health expands nationwide.
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Limitations
This standardized protocol is specific to Ria Health. For example, Ria Health
clinicians prescribe naltrexone differently than compared to other clinics. The initial
naltrexone dose prescribed to patients is 12.5mg (quarter tablet) for two days, then
25mg (half-tablet) for two days, then 50mg thereafter. In the past, higher dosages for
naltrexone, such as 25mg – 50mg, immediately lead to nausea and GI upset, which
resulted to poor medication compliance in patients. Lowered naltrexone dosages
initially, was therefore used in favor to increase better compliance.
Another limitation is that some nurse practitioners do not want to work under a
standardized protocol after working independently in other states. They are resistant to
change even though they are required by law to work under standardized protocols in
some states. The Ria Health leadership team is not enforcing the standardized protocol
on nurse practitioners who refuse. Having their nurse practitioners practice legally in
California is simply not a priority for Ria Health. This in turn places a huge liability to
the company and to some nurse practitioner(s) who are required by law to work under
standardized protocols.
Conclusions
The standardized protocols that were created and implemented are specific to how Ria
Health treats AUD in the telehealth setting. (See Appendix H). The standardized protocol
implemented at Ria Health does not apply to other settings unless another clinic is using a treatment
platform similar to Ria Health. At this time, the Ria Treatment Platform appears to be the only
telehealth service that incorporates physician-prescribed medication and a recovery coach
(Mitchell et al., 2019). Other outpatient clinics or community organizations like Alcohol
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Anonymous aim for the goals of sobriety and abstinence for their patients. Ria Health’s aim is help
patients achieve their goals whether it be drinking less or not at all. With the possibility of future
telehealth alcohol addiction programs appearing, these standardized protocols can be used as
sample guidelines and modified for other clinics to meet their needs by providing patient safety
and to set a legal framework for nurse practitioners. Although existing research supports the use
of nurse practitioners in primary care, no evidence is available about nurse practitioners working
in the specialty field environment of AUD. Further research that explores the impact of nurse
practitioners employed in the AUD setting is needed. The immediate goal was to have Ria Health
exit the mindset of ad hoc judgments, or freelance mentality. Ria Health will need to wed all the
nurse practitioners (who lack the “transition to practice in California” requirements) to the
standardized protocols. In the aggregate, this produces better outcomes. It will increase the nurse
practitioners’ autonomy and body of knowledge as well as provide guidance for AUD treatment
and improve patient care outcomes.
Funding
All costs involved in the development and implementation of the project were
solely incurred by the DNP student/project director without external funding.
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Appendix E
Gap Analysis

Best Practice

Best Practice
Strategies

Standardize
protocol for AUD
at Ria Health

Collaboration
between Ria
Health and
Nurse
Practitioners
employed at Ria
Health
Signed
standardized
AUD protocol
between Medical
Director and
Nurse
practitioners

How the site
practices differ
from Best
Practices

Barriers to Best
Practice
Implementation

Will Implement
Best Practice
(Yes/No, why
not?)

Siloed
stakeholder
activities

Historical use of
ad hoc judgment

Yes

Absence of
standardized
protocol used at
Ria Health

Perceived lack
of focused
collaboration

Yes
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Appendix G
AUD Standardized Procedure
Standardized Procedure
FACILITY: Ria Health__
POLICY
I.

FUNCTIONS NURSE PRACTITIONERS MAY PERFORM:
Provide care for patients with alcohol use disorder as covered in attached protocol
and furnish non-controlled/controlled drugs and devices to essentially healthy patients.

II.

CIRCUMSTANCES UNDER WHICH NURSE PRACTITIONERS MAY PERFORM
THESE FUNCTIONS:
A. May furnish non-controlled/controlled drugs and devices under standardized
procedures under the supervision of John Mendelson, MD and other appropriately
licensed and credentialed Ria Health physicians.
B. Applies to nurse practitioners working at Ria Health.

III.

EXPERIENCE, TRAINING AND/OR EDUCATION REQUIRED OF THE NURSE
PRACTITIONER:
Maintains a current California license to practice as an RN; is certified by the
State of California as a Nurse Practitioner; has met all the requirements for, and has a
current Furnishing Number issued by the Board of Registered Nursing; is oriented to the
facility.

IV.

METHOD OF INITIAL AND CONTINUED EVALUATION OF COMPETENCE:
General competency is initially evaluated during the probationary period through
a proctoring process by the Chief Medical Officer of Ria Health, John Mendelson, MD,
or the appropriately licensed and credentialed Ria Medical staff physicians. [Insert Name]
NP is assigned to, and is supervised by, John Mendelson, MD, who is responsible to
evaluate annually appropriateness of practice and clinical decision making. A QA review
process is established to assure that compliance to standards relating to important aspects
of care are maintained.

V.

DOCUMENTATION
Documentation required is outlined in each protocol. Patient specific
documentation is entered into the patient’s medical record.
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DEVELOPMENT AND APPROVAL OF THE STANDARDIZED PROCEDURE
I. THIS STANDARDIZED PROCEDURE WAS:
Developed and approved by John Mendelson, MD, and [Insert Name] NP.
II. THIS STANDARDIZED PROCEDURE WILL BE REVIEWED AT LEAST ANNUALLY.
REVISION DATED ___________ REVIEWED DATED __________
___________
___________

__________
__________

III. THE STANDARDIZED PROCEDURE WAS APPROVED BY:
____________________________________

DATE____________

____________________________________

DATE____________

John Mendelson MD

[Insert Name] NP
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IV. PRACTITIONERS FUNCTION UNDER THIS STANDARDIZED PROCEDURE:
[Insert Name/s] NP
PROTOCOLS
Alcohol Use Disorder (AUD)
References:
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ALCOHOL USE DISORDER (AUD) PROTICOL:
I. RATIONALE
This protocol will assist in the diagnosis and management of AUD. The design of the
protocol for AUD encompasses these principles.
II. DIAGNOSTIC CRITERIA (DSM-5)
Alcohol use disorder is defined as a problematic pattern of alcohol use leading to
clinically significant impairment or distress as manifested by at least 2 of the following criteria
over the same 12-month period:
1. Alcohol used in larger amounts or over a longer period of time than intended
2. Persistent desire or unsuccessful attempts to reduce or to control alcohol use
3. Significant time spent obtaining, using, and recovering from the effects of alcohol
4. Craving to use alcohol
5. Recurrent alcohol use leading to failure to fulfil major role obligations at work, school, or
home
6. Recurrent use of alcohol, despite having persistent or recurring social or interpersonal
problems caused or worsened by alcohol
7. Recurrent alcohol use despite having persistent or recurring physical or psychological
problems caused or worsened by alcohol
8. Giving up or missing important social, occupational, or recreational activities due to
alcohol use
9. Recurrent alcohol use in hazardous situations
10. Tolerance: markedly increased amounts of alcohol are needed to achieve intoxication or
the desired effect, or continued use of the same amount of alcohol achieves a markedly
diminished effect
11. Withdrawal: characteristic alcohol withdrawal syndrome, or alcohol is taken to relieve or
to avoid withdrawal symptoms.
Severity is specified based on the number of criteria met: mild alcohol use disorder when 2 to 3
criteria are met, moderate alcohol use disorder when 4 to 5 criteria are met, and severe alcohol
use disorder when 6 or more criteria are met. Remission is specified when no criteria, other than
cravings, are met for at least 3 months (early remission) or 12 months (sustained remission).
III. HISTORY
A. Ask about patient’s drinking goal, current drinking habits (amount, frequency,
variability, time at current level), cravings, specific drinking precipitants.
B. Assess contribution of pain (acute or chronic), medical diseases and prior surgeries
(bariatric) to drinking.
C. Ask about drinking history, withdrawal symptoms, sleep patterns, complications of
drinking, risky behaviors, problems related to drinking, health problems associated with
drinking, prior treatments tried and results, readiness to change
D. Assess concurrent abuse of stimulants, opioids and cannbionoids.
E. Ask about psychiatric disease. Review past and current psychiatric diagnoses and
symptoms
F. Evaluate suicidal ideation and risks (plans, means)
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G. Ask about prior treatment of addictive disorders.
H. Perform a review of systems
IV. PHYSICAL EXAM
A. Perform mental status exam
V. DIFFERENTIAL DIAGNOSIS
A. Other psychiatric disorders
B. Other substance use disorders
VI. LAB TESTS
A. CBC with diff
B. CMP including AST and ALT
C. PT/INR
D. gamma-glutamyl transpeptidase (ggt)
E. phosphatidylethanol
F. transferrin, carbohydrate-deficient/total
G. ethyl glucuronide
VII. ASSESSMENT & TREATMENT
A. Refer patients to a higher level of care (Erm residential program) if they score 3 on
more than 1 dimension of the ASAM Level of Determination Questionnaire.
B. INITIAL VISIT
1. Counsel patients that they will start using the mobile Bluetooth breathalyzer
twice a day to establish baseline data on alcohol levels and drinking patterns.
This will track alcohol use with the Ria Health mobile app.
2. Inform clients to continue drinking their usual amount in order to get accurate
breathalyzer readings for one week.
3. Inform clients that they will meet with both a personal coach to discuss goals,
and the medical team to discuss care plan, and if desired, obtain medication
management to reduce alcohol cravings.
4. Order Labs
5. Prescribe thiamine (vitamin B1) 100mg PO daily for the first 30 days of
treatment.
6. Follow up in 1-week to evaluate baseline data.
C. FOLLOW-UP VISIT
1. Prescribe gabapentin
a. Initial: 300 mg once daily; increase dose based on response and
tolerability in increments of 300 mg every 1 to 2 days up to a
maximum dose of 2700mg/day.
i. The addition of gabapentin to naltrexone improved drinking
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outcomes over naltrexone alone during the first six weeks after
cessation of drinking (Anton et al. 2012; Anton et al. 2006).
ii. Gabapentin has an off-label use to treat those with moderate to
severe alcohol use disorder, and comorbid insomnia (Brower
2008; Mason 2014; VA/DoD 2015).
b. Provide education to client on the side effects of gabapentin. See
Table 1.
2. Determine which first-line treatment to use
a. If patient is opioid free for at least 7 days,
i. Prescribe naltrexone if not contradicted
1. Naltrexone should be used cautiously in people who
have alanine aminotransferase (ALT) concentrations
greater than 3–5 times the normal limit, and is
contradicted in acute hepatitis or liver failure. However,
continued heavy drinking is more likely to pose a
greater risk to liver function than naltrexone. Arguably,
the risk−benefit analysis likely favors naltrexone
treatment (Yen et al. 2006; Crowley 2015).
2. Naltrexone is contradicted if patient is on atypical
opioids such as Kratom (Eastlack, Cornett, & Kay,
2020).
ii. To decrease gastrointestinal side effects, start with 25 mg PO
with food 1-2 hours prior to anticipated alcohol ingestion, and
gradually titrate the dose to 50mg PO once daily
1. If GI side effects persists
a. Start with dose of 12.5mg and slowly titrate up
to 50mg
b. Or adjust the administration times (e.g.
naltrexone 25mg BID)
iii. Naltrexone dosing is 50 mg/day. Increase dose gradually based
on clinical response and tolerability in increments of 25 mg
every 4 to 6 weeks up to a maximum dose of 200 mg/day.
iv. Provide education to client on the side effects of naltrexone.
See Table 1.
b. If patient is currently taking opioids:
i. Consider prescribing baclofen if not contradicted
1. Dose range 5 mg PO TID, up to a maximum dosage of
160 mg/day (e.g. 40mg QID). Baclofen dose needs
careful titration over weeks.
2. The optimum dose generally ranges between 30 mg and
75 mg (Crowley 2015)
3. Slowly taper baclofen when it is discontinued to avoid
serious adverse reactions (e.g. seizures or confusion).
ii. Provide education to client on the side effects of baclofen. See
Table 1.
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c. Alternative option if patient is currently taking opioids:
i. Consider prescribing topiramate if not contradicted
1. Dosing requires slow titration from 25 mg daily to a
maximum of 150 mg twice daily.
ii. Provide education to client on the side effects of topiramate.
See Table 1.
d. If patient is abstinent and wants to maintain sobriety:
i. Consider prescribing acamprosate 666mg PO TID
1. Renal dosing CrCl 30-50: 333mg TID
ii. Consider adding targeted naltrexone dosing to reduce relapse
rates after abstinence
3. Follow-up in 1-month or sooner if having adverse reactions or intolerable side
effects
D. MAINTENANCE VISIT
1. Gabapentin
a. Continue if no adverse side effects; titrate to maximum dose or 2700
mg/day
b. If having adverse effects, consider decreasing the dose
2. Naltrexone
a. If nonadherence, switch to depot naltrexone
b. If having a partial response or no response, consider increasing
naltrexone dosage by 25mg to a maximum of 150 mg/day
i. Follow-up in 1 month, or sooner if needed
c. If responding well, continue current treatment plan
i. Follow-up in 2 months, or sooner if needed
3. Baclofen
a. If responding well, continue current treatment plan
b. If having partial response, consider increasing the dose to a max of 90
mg/day; can titrate to 120 after MD consultation
c. If having no response or having adverse effects, consider decreasing
dose and/or switching to another AUD medication, if not contradicted.
i. Consult with Medical Director
4. Topiramate
a. If responding well, continue current treatment plan
b. If having partial response, consider increasing the dose
c. If having no response, consider increasing the dose to a maximum of
400 mg/day, adding and/or switching to another AUD medication, if
not contradicted.
i. Consult with Medical Director
5. Acamprosate
a. If responding well, continue current treatment plan
b. If partial response, considering adding another AUD medication.
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c. If no response, consider adding/or switching to another AUD
medication, if not contradicted.
i. Consult with Medical Director
AUD PROTICOL: TREATMENT FAILURE
If the patient calls in with persistent or recurrent symptoms after unsuccessful treatment,
consult with the attending physician.
Protocol developed by: ____________________________, NP
[Insert Name]
____________________________, MD
John Mendelson
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Table 1. Pharmacotherapy for alcohol use disorder (AUD).
Medication1

Dosing2

Naltrexone

50 mg once
daily and can
increased up to
100mg daily

380 mg
monthly
for
intramuscular
formulation
Acamprosate 333 mg tablets
2 tablets TID for
weight >132 lbs
and 2 tablets
BID for weight
<132 lbs
Topiramate

*Renal dosing
Begin at 25 mg
daily and can
increase to up to
150 mg twice
daily
*Renal dosing

Gabapentin

Begin at 300 mg
once daily and
can increase to
up to 900 mg
three times daily
*Renal dosing

Side effects and
monitoring3
Nausea, vomiting,
decreased appetite,
anxiety, hepatocellular
injury, suicidality
Injection site reactions
for the intramuscular
formulation
Monitor liver function
Diarrhea, nausea,
flatulence, anxiety,
depression, suicidality
Monitor renal function

Sedation, dizziness,
ataxia, paresthesia,
psychomotor retardation,
speech difficulties,
tremor, nausea, cognitive
function, metabolic
acidosis
Monitor electrolytes
Sedation, dizziness,
ataxia, fatigue, tremor,
xerostomia, constipation,
weight gain, peripheral
edema, sudden death
(when used in epilepsy)
and suicidality
Monitor renal function

Medicolegal tips, other indications
and contraindications4
- Patient must be opioid-free for 7-10
days prior to initiation
- Discontinue if opioid-based
anesthesia is anticipated
- Warn patients of potential for
hepatotoxicity
- Contraindicated in acute hepatitis or
liver failure
- Recommend for patients who are
alcohol free for at least 3 days
- Contraindicated in patients with
creatinine clearance less than 30 mL
per minute
- Indicated for epilepsy, migraine
prophylaxis, chronic weight
management
- Non-FDA use for bipolar disorder,
psychotropic drug –induced weight
gain, binge-eating disorder

- Indicated for post-herpetic
neuralgia, adjunctive therapy in
epilepsy, restless leg syndrome
- Non-FDA use for fibromyalgia,
anxiety, bipolar disorder
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Table 1. Pharmacotherapy for alcohol use disorder (AUD) continued.
Medication1

Dosing2

Baclofen

Begin at 5 mg
three times
daily, may
increase up to
20 mg four
times daily
Depends on
choice of SSRI

SSRI4

Side effects and
monitoring3
Dizziness, drowsiness,
fatigue, weakness, CNS
depression respiratory
depression, seizures

Medicolegal tips, other indications
and contraindications4
- Indicated for spasticity
- Non-FDA use for intractable
hiccups

Constipation,
flatulence, insomnia,
sedation, tremor,
headache, dizziness,
sweating, sexual
dysfunction, seizures,
mania, suicidality
Sedation, fatigue,
depression, dizziness,
ataxia, slurred speech,
weakness,
forgetfulness, confusion

- Indicated for mood, anxiety,
obsessive compulsive disorders,
eating disorders, but depends on the
choice of SSRI
- Use with caution in patients with
history of seizures or bipolar
disorder
-Indicated for withdrawal symptoms
of acute alcoholism

Chlordiazepoxide Depends on
clinical
presentation.
Recommended
- Contradicted in patients with
dosing range
angle-closure glaucoma
5mg daily to
10mg TID for
2-3 days
1
FDA (U.S. Food and Drug Administration) approved medications for treatment of AUD
indicated in bold.
2
All dosing in oral route unless otherwise indicated.
3
More common side effects are highlighted in bold
4
Selective serotonin reuptake inhibitors.
*Indicates drug dosing considerations for patients with hepatic or renal impairments
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Figure 1.

Suggested treatment algorithm for alcohol use disorder (AUD)

Healthy or
Kidney disease
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use disorder
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opioid use
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active opioid use

Naltrexone

Nonadherence
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naltrexone

Partial
Response

Consider
combination
therapy with
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Acamprosate

Unipolar depression or PTSD

SSRI

Smoking cessation
Off-label agents to consider when
first-line agents not effective, not
tolerated or contraindicated, or when
indicated for comorbid conditions
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Spasticity

Neuropathy
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Appendix I
Work Breakdown Structure

PROJECT TITLE

Standarized Protocols

PROJECT MANAGER

Crystal Jade Dea

Apr-20

COMPANY NAME

DATE

Creatiion of Standardized
Protocols for Nurse
Practitioners in a
Telehealth AUD Program

PROJECT

PHASE

Ria Health

Planning

Implementation

Evaluation

Needs Analysis

Conduct Orientation Training

Measure Satisfaction Levels

SWOT Analysis

Obtain Survey Questionaire Data

Measure Confidence Levels

GANTT Chart
TASK
Literature Review

Budget

Submission to USF

Obtain Approval of Meical Director
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Responsibility/Communication Matrix

Task
USF Approval
Formulate SP
Implement SP
Evaluate SP
P
C
A
I

CJ Dea
Project Lead
I
P
C
P

John Mendelson,
Medical Director
I
C
P
C

Primary Actor
Critique (review and comment)
Approve
Inform

Trinette Rasada
NP/USF Advisor
P
C
C
C

Tom Nix
VC Investor
I
A
I
I
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Appendix L
Project Budget
Budget Item
Project Manager Expense
Salary in Project Development &
Implementation
Training two Nurse practitioners at Ria
Supplies and Resources
Office Supplies
Cost for The Student Satisfaction and
Self-Confidence in Learning
Questionnaire
Total

Description
$50/hour x 315 hours ($15,750 inkind)
$50/hr x 15 mins x 2NP= ($25 inkind)
Paper, binders, post-its,
photocopying, ink cartridge
Free unlimited use

Estimated Cost

$15,750
$25.00

$100.00
$0.00
$15875.00
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Appendix N
Revised Student Satisfaction and Self-Confidence in Learning Questionnaire

Student Satisfaction and Self-Confidence in Learning
Instructions: This questionnaire is a series of statements about your personal attitudes about the
instruction you receive during your orientation activity. Each item represents a statement about your
attitude toward your satisfaction with learning and self-confidence in obtaining the instruction you
need. There are no right or wrong answers. You will probably agree with some of the statements and
disagree with others. Please indicate your own personal feelings about each statement below by
marking the numbers that best describe your attitude or beliefs. Please be truthful and describe your
attitude as it really is, not what you would like for it to be. This is anonymous with the results being
compiled as a group, not individually.
Mark:
1 = STRONGLY DISAGREE with the statement
2 = DISAGREE with the statement
3 = UNDECIDED - you neither agree or disagree with the statement
4 = AGREE with the statement
5 = STRONGLY AGREE with the statement
Satisfaction with Current Learning

SD

D

UN

A

SA

1. The teaching methods used in this orientation were helpful and effective.

○1

○2

○3

○4

○5

2. The orientation provided me with a variety of learning materials and activities to
promote my learning the alcohol use disorder protocol.

○1

○2

○3

○4

○5

3. I enjoyed how my instructor taught the orientation.

○1

○2

○3

○4

○5

4. The teaching materials used in this orientation were motivating and helped me
to learn.

○1

○2

○3

○4

○5

5. The way my instructor(s) taught the orientation was suitable to the way I learn.

○1

○2

○3

○4

○5

Self-confidence in Learning

SD

D

UN

A

SA

○1

○2

○3

○4

○5

○1

○2

○3

○4

○5

○1

○2

○3

○4

○5

○1

○2

○3

○4

○5

○1

○2

○3

○4

○5

○1

○2

○3

○4

○5

12. I know how to use orientation activities to learn critical aspects of these skills.

○1

○2

○3

○4

○5

13. It is the instructor's responsibility to tell me what I need to learn of the
orientation activity content during class time.

○1

○2

○3

○4

○5

6. I am confident that I am mastering the content of the orientation activity that my
instructor presented to me.
7. I am confident that this orientation covered critical content necessary
for the mastery of alcohol use disorder protocol.
8. I am confident that I am developing the skills and obtaining the required
knowledge from this orientation to perform necessary tasks in a clinical setting
9. My instructor used helpful resources to teach the orientation.
10. It is my responsibility as the student to learn what I need to know from this
orientation activity.
11. I know how to get help when I do not understand the concepts covered
in the orientation.
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